FTV:NYSEFortive Corporation Analysis
Data as of 2026-05-27 - not real-time
$60.32
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Fortive (FTV) is trading at $60.32, comfortably above its 20‑day SMA ($59.86) and 50‑day SMA ($58.50) while staying under the 200‑day SMA ($53.95), confirming a bullish trend despite a bearish MACD histogram and decreasing volume. The RSI sits at 56, indicating neutral momentum, and the stock sits between a solid support level of $57.38 and a resistance near $62.81, offering a modest upside cushion. Volatility of 17.3% over the past 30 days and a low beta of 0.73 suggest limited systematic risk, while the extreme greed sentiment (91.07) reflects strong market optimism. Fundamentally, revenue grew 7.7% year‑over‑year to $4.24 B, with healthy gross (63%) and operating (18%) margins, and free cash flow of $953 M supports ongoing operations. The balance sheet shows a high debt‑to‑equity ratio of 58.8, but cash on hand ($356 M) and strong operating cash flow ($1.08 B) mitigate liquidity concerns. The current PE of 35.5 is below the industry average of 40.6, and a forward PE of 18.8 signals earnings acceleration, while the DCF fair value ($45.97) suggests the market is pricing in growth expectations. Analysts project a median target of $64, implying a modest upside of about 5% from today’s price. Recent material news highlights an expanded share repurchase authorization (20 M shares) and a $1.1 B senior note issuance, underscoring management’s confidence in capital allocation. The dividend yield of 0.43% with a 15% payout ratio appears sustainable given robust cash generation. Overall, the stock balances growth momentum with a fair valuation, supported by strategic buybacks and solid cash flow.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price above short‑term moving averages with support at $57.38
- Bearish MACD histogram and decreasing volume
- Expanded share repurchase program adds upside potential
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward PE compression to 18.8 and earnings growth
- Revenue growth of 7.7% with strong margins
- Analyst median target of $64 indicating upside
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High debt level balanced by strong free cash flow
- Sustainable dividend with low payout ratio
- Fair valuation relative to DCF and industry peers
Key Metrics & Analysis
Financial Health
Revenue Growth7.70%
Profit Margin12.84%
P/E Ratio35.5
ROE6.81%
ROA3.25%
Debt/Equity58.81
P/B Ratio3.0
Op. Cash Flow$1.1B
Free Cash Flow$953.6M
Industry P/E40.6
Technical Analysis
TrendBullish
RSI56.1
Support$57.38
Resistance$62.81
MA 20$59.86
MA 50$58.50
MA 200$53.95
MACDBearish
VolumeDecreasing
Fear & Greed Index91.07
Valuation
Fair Value$45.97
Target Price$63.40
Upside/Downside5.11%
GradeFair
TypeGrowth
Dividend Yield0.43%
Risk Assessment
Beta0.73
Volatility17.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.